LLY News and Press, Eli Lilly and Company From 12/29/23

2023-12-29 14:54:46 ET Summary I review the stocks of five world-class companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends. I point out the specifics of the companies' business models, discuss their pro...

2023-12-28 19:28:29 ET Summary Fidelity® Quality Factor ETF holds 126 stocks with quality characteristics. The FQAL ETF focuses on higher profitability, stable cash flows, and good balance sheets, with a sector-neutral methodology. FQAL has slightly lagged the S&P 500...

2023-12-28 15:06:23 ET More on AbbVie, Amgen, etc. The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Bristol Myers Squibb: Too Many Headwinds To Ignore, Despit...

2023-12-28 08:30:00 ET When it comes to the pharmaceutical industry , weight-loss medications are all the rage right now. While Ozempic maker Novo Nordisk dominates medications designed to treat obesity and diabetes, two other companies are looking to get their slice of the pie ...

2023-12-28 04:13:45 ET More on Innovent Biologics: Innovent marks China's first regulatory review of a KRAS G12C inhibitor Historical earnings data for Innovent Biologics Financial information for Innovent Biologics For further details see: Innovent Biolo...

2023-12-28 01:30:44 ET Summary Pfizer is one of the largest American pharmaceutical companies, developing medicines and vaccines using cutting-edge technologies to save and improve the lives of millions worldwide. Pfizer's revenue for the three months that ended in 2023 was about ...

2023-12-27 13:55:07 ET More on Eli Lilly: Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) Eli Lilly: Long Path To A Trillion Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly FDA’s ne...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

2023-12-27 11:03:53 ET More on Fusion Pharmaceuticals RBC says Bristol Myers/RayzeBio deal validates Fusion 's approach Fusion Pharma shares jump following expanded actinium supply deal with BWXT Seeking Alpha’s Quant Rating on Fusion Pharmaceuticals H...

2023-12-27 09:10:12 ET More on Eli Lilly Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) Eli Lilly: Long Path To A Trillion Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly Eli Lilly purcha...